ATEC vs. ATRC, IART, OFIX, SRDX, LMAT, MDXG, AORT, NVCR, EMBC, and ATRI
Should you be buying Alphatec stock or one of its competitors? The main competitors of Alphatec include AtriCure (ATRC), Integra LifeSciences (IART), Orthofix Medical (OFIX), Surmodics (SRDX), LeMaitre Vascular (LMAT), MiMedx Group (MDXG), Artivion (AORT), NovoCure (NVCR), Embecta (EMBC), and Atrion (ATRI). These companies are all part of the "surgical & medical instruments" industry.
AtriCure (NASDAQ:ATRC) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations.
AtriCure has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.
AtriCure has higher earnings, but lower revenue than Alphatec. AtriCure is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.
AtriCure has a net margin of -8.98% compared to AtriCure's net margin of -37.45%. Alphatec's return on equity of -7.85% beat AtriCure's return on equity.
AtriCure presently has a consensus target price of $49.78, indicating a potential upside of 115.12%. Alphatec has a consensus target price of $22.89, indicating a potential upside of 107.14%. Given Alphatec's higher possible upside, research analysts plainly believe AtriCure is more favorable than Alphatec.
AtriCure received 233 more outperform votes than Alphatec when rated by MarketBeat users. Likewise, 68.98% of users gave AtriCure an outperform vote while only 56.68% of users gave Alphatec an outperform vote.
In the previous week, AtriCure had 3 more articles in the media than Alphatec. MarketBeat recorded 6 mentions for AtriCure and 3 mentions for Alphatec. AtriCure's average media sentiment score of 0.60 beat Alphatec's score of 0.47 indicating that Alphatec is being referred to more favorably in the news media.
99.1% of AtriCure shares are owned by institutional investors. Comparatively, 66.4% of Alphatec shares are owned by institutional investors. 3.2% of AtriCure shares are owned by company insiders. Comparatively, 29.1% of Alphatec shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
AtriCure beats Alphatec on 10 of the 17 factors compared between the two stocks.
Get Alphatec News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATEC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alphatec Competitors List
Related Companies and Tools
